

## Medical Policy



### Aerochamber: Drug Delivery Systems for Metered Dose Inhaler (MDI)

#### Description

Drug delivery systems are either reservoirs or bags used with a metered-dose inhaler that enables a patient to breathe or inhale a fixed dose of his/her medication.

#### Policy

##### Medicare members:

An A4627, S8100 and S8101 are noncovered under Medicare.

##### Non-Medicare members:

A drug delivery system for metered dose inhaler (MDI) is considered **reasonable and necessary** to enable a member to breathe or inhale a fixed dose of medication.

A drug delivery system for a metered dose inhaler (MDI) is considered **not reasonable and necessary** for all other indications.

#### Policy Guidelines

##### Coverage Criteria:

1. Must be ordered by the member's treating practitioner.

##### Limitations:

1. One reservoir bag allowed per month.
2. One holding chamber is allowed per year.

#### HCPCS Level II Codes and Description

A4627	Spacer bag or reservoir, with or without masks, for use with metered dose inhaler
S8100	Holding chamber or spacer for use with an inhaler or nebulizer; without mask
S8101	Holding chamber or spacer for use with an inhaler or nebulizer; with mask

#### Documentation Requirement

1. Provider must submit supporting documentation with claim that shows documentation of metered dose inhaler (MDI) medication.

## Medical Policy



### **Aerochamber: Drug Delivery Systems for Metered Dose Inhaler (MDI)**

#### **Important Note:**

Northwood's Medical Policies are developed to assist Northwood in administering plan benefits and determining whether a particular DMEPOS product or service is reasonable and necessary. Equipment that is used primarily and customarily for a non-medical purpose is not considered durable medical equipment.

Coverage determinations are made on a case-by-case basis and are subject to all of the terms, conditions, limitations, and exclusions of the member's contract including medical necessity requirements.

The conclusion that a DMEPOS product or service is reasonable and necessary does not constitute coverage. The member's contract defines which DMEPOS product or service is covered, excluded or limited. The policies provide for clearly written, reasonable and current criteria that have been approved by Northwood's Medical Director.

The clinical criteria and medical policies provide guidelines for determining the medical necessity for specific DMEPOS products or services. In all cases, final benefit determinations are based on the applicable contract language. To the extent there are any conflicts between medical policy guidelines and applicable contract language, the contract language prevails. Medical policy is not intended to override the policy that defines the member's benefits, nor is it intended to dictate to providers how to direct care. Northwood Medical policies shall not be interpreted to limit the benefits afforded to Medicare or Medicaid members by law and regulation and Northwood will use the applicable state requirements to determine required quantity limit guidelines.

Northwood's policies do not constitute medical advice. Northwood does not provide or recommend treatment to members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Northwood follows all CMS National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), as applicable.

#### **References**

1. National Institutes of Health (NIH), National Heart, Lung and Blood Institute (NHLBI). Patient education. In: Guidelines for the Diagnosis and Management of Asthma. National Asthma Education Program, Expert Panel Report. J Allergy Clin Immunol. 1991;88(3 Pt 2):460-472. Last accessed/reviewed November 9, 2023.

## Medical Policy



### **Aerochamber: Drug Delivery Systems for Metered Dose Inhaler (MDI)**

2. Aetna Peak Flow Meter, CPB 0059  
[https://www.aetna.com/cpb/medical/data/1\\_99/0059.html](https://www.aetna.com/cpb/medical/data/1_99/0059.html) Last accessed and reviewed 11/5/25.
3. Autio L, Rosenow D. Effectively managing asthma in young and middle adulthood. *Nurse Pract.* 1999;24(1):100-111.
4. Everard ML. Guidelines for devices and choices. *J Aerosol Med.* 2001;14 Suppl 1:S59-S64.
5. Gazarian M, Henry RL, Wales SR, et al. Evaluating the effectiveness of evidence-based guidelines for the use of spacer devices in children with acute asthma. *Med J Aust.* 2001;174(8):394-397.
6. Lakamp RE, Berry TM, Prosser TR, Baher TD. Compatibility of spacers with metered-dose inhalers. *Am J Health Syst Pharm.* 2001;58(7):585-591.
7. Meurer JR, George V, Subichin SJ, et al. Risk factors for pediatric asthma emergency visits. Milwaukee Childhood Asthma Project Team. *J Asthma.* 2000;37(8):653-659.
8. Brand PL. Inhalation therapy in children with asthma. *Minerva Pediatr.* 2000;52(3):137-142.
9. Dhand R. Aerosol therapy for asthma. *Curr Opin Pulm Med.* 2000;6(1):59-70.
10. Aronson N, LeFevre F, Piper M, et al. Management of chronic asthma. Evidence Report/Technology Assessment No. 44. Prepared for AHRQ by the BlueCross BlueShield Association Technology Evaluation Center Evidence-Based Practice Center. AHRQ Pub. No. 01-E044. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); September 2001.
11. Tovar JM, Gums JG. Monitoring pulmonary function in asthma and COPD: Point-of-care testing. *Ann Pharmacother.* 2004;38(1):126-133.
12. Gibson PG, Powell H, Coughlan J, et al. Self-management education and regular practitioner review for adults with asthma. *Cochrane Database Syst Rev.* 2002;(3):CD001117.
13. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. *Cochrane Database Syst Rev.* 2006;(2):CD000052.

## Medical Policy



### Aerochamber: Drug Delivery Systems for Metered Dose Inhaler (MDI)

14. Rodriguez C, Sossa M, Lozano JM. Commercial versus home-made spacers in delivering bronchodilator therapy for acute therapy in children. Cochrane Database Syst Rev. 2008;(2):CD005536.

#### Change/Authorization History

Revision Number	Date	Description of Change	Prepared/Reviewed by	Approved by	Review Date:	Effective Date:
A	Nov.2006	Initial Release	Rosanne Brugnani	Ken Fasse	n/a	
01		Annual Review-no changes	Susan Glomb	Ken Fasse	Dec. 2008	
02	12-22-09	Annual Review- No changes	Susan Glomb	Ken Fasse	Dec.2009	
03	12-15-10	Annual review/ no changes	Susan Glomb	Ken Fasse	Dec.2010	
05	07-20-11	Added Important Note to all Medical Policies	Susan Glomb	Dr. B. Almasri		
06	11-09-11	Annual Review. Added References to Policy	Susan Glomb	Dr. B. Almasri	Nov. 2011	
07	04-03-12	Added reference to NH Medicaid	Susan Glomb	Dr. B. Almasri		
08	11-28-12	Annual Review – No changes	Susan Glomb	Dr. B. Almasri	Nov 12	
09	12-30-13	Annual review. No changes	Susan Glomb	Dr. B. Almasri		
10	11-24-14	Annual Review. No changes	Susan Glomb	Dr. B. Almasri		
11	12-14-15	Annual Review. Updated policy to reflect codes are noncovered under Medicare.	Lisa Wojno	Dr. B. Almasri	12-14-15	
12	11-22-16	Annual Review. No Changes.	Lisa Wojno	Dr. B. Almasri	11-22-16	

## Medical Policy



### Aerochamber: Drug Delivery Systems for Metered Dose Inhaler (MDI)

13	11-14-17	Annual review. No changes.	Carol Dimech	Dr. C. Lerchin	11-14-17	
14	11-08-18	Annual Review. No Changes.	Lisa Wojno	Dr. C. Lerchin	11-08-18	
15	11-08-19	Annual Review. No Changes.	Lisa Wojno	Dr. C. Lerchin	November 2019	11-2019
16	11-09-20	Annual Review. No Changes.	Carol Dimech	Dr. C. Lerchin	November 9, 2020	November 9, 2020
17	11-23-21	Annual review. Replaced “prescribing physician” to state “prescribing practitioner”. Added LCD/NCD verbiage to Important Note.	Carol Dimech	Dr. C. Lerchin	November 23, 2021	11-23-21
18	11-15-22	Annual review. Added reference.	Carol Dimech	Dr. C. Lerchin	11-15-22	11-15-22
19	11-9-23	Annual review. No changes.	Carol Dimech	Dr. C. Lerchin	11-9-23	11-9-23
20	11-11-24	Annual review. No changes.	Carol Dimech	Dr. C. Lerchin	11-11-24	11-11-24
21	11-5-25	Annual review. No changes.	Carol Dimech	Dr. C. Lerchin	11-5-25	11-5-25